FGFR2 and urothelial carcinoma: The Cancer Genome Atlas Research Network found a FGFR3 mutation rate of 12% upon sequencing of a retrospective cohort of 130 chemotherapy-naive, T2 to T4a high-grade urothelial carcinomas.27 Using a prospective cohort of metastatic or unresectable, locally advanced urothelial carcinoma, Loriot and colleagues10 identified actionable FGFR2/3 alterations in 16.6% of 7293 patients.